Skip to main content

Advertisement

Table 2 Unadjusted HR estimates of the treatment effect for DFS and OS according to Prosigna ROR scores and subtype

From: The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

  DFS OS
HR (95% CI) Pinteraction HR (95% CI) P interaction
ROR score    0.47    0.24
 Low tertile 0.79 (0.42–1.47)   1.09 (0.70–1.71)  
 Intermediate tertile 0.49 (0.30–0.79)   0.75 (0.50–1.13)  
 High tertile 0.64 (0.42–0.98)   0.66 (0.46–0.96)  
Subtype    0.003    0.04
 Luminal A 0.64 (0.36–1.14)   0.96 (0.62–1.48)  
 Luminal B 0.47 (0.28–0.77)   0.51 (0.33–0.77)  
 Basal-like 0.19 (0.09–0.40)   0.52 (0.24–1.12)  
 Her2-enriched 1.04 (0.62–1.75)   1.10 (0.71–1.71)  
  1. DFS disease-free survival, OS overall survival, HR hazard ratio, ROR risk of recurrence, 95% CI 95% confidence interval, Pinteraction P derived from a Wald test for heterogeneity, Her2 human epidermal growth factor receptor 2